Search
MB-107
go.drugbank.com/drugs/DB18566ExperimentalMB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
Allitinib
go.drugbank.com/drugs/DB18840ExperimentalAllitinib is under investigation in clinical trial NCT04671303 (To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer).
AZD8529
go.drugbank.com/drugs/DB16073InvestigationalAZD8529 is under investigation in clinical trial NCT00921804 (Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients).
BCG vaccine
go.drugbank.com/drugs/DB12768ApprovedInvestigationalWithdrawnBCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
Alatrofloxacin
go.drugbank.com/drugs/DB09335ApprovedWithdrawnIt was withdrawn from the U.S. market in 2001.
(R)-acetoin
go.drugbank.com/drugs/DB04364ExperimentalIt is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
(S)-acetoin
go.drugbank.com/drugs/DB02788ExperimentalIt is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Trefoil Factor 2
go.drugbank.com/drugs/DB15750ExperimentalThe peptides themselves are most abundant in mucous cells of the gastric mucosa with TFF2 being detected in mucous layers over the tissue. … The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins.
Probiorinse
go.drugbank.com/drugs/DB15870Experimental[L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193] … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.
Idraparinux
go.drugbank.com/drugs/DB06406InvestigationalAs a result, Sanofi stopped the development of the drug. … It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding.